» Articles » PMID: 15361282

Chemokine-like Factor 1, a Novel Cytokine, Contributes to Airway Damage, Remodeling and Pulmonary Fibrosis

Overview
Specialty General Medicine
Date 2004 Sep 14
PMID 15361282
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chemokine-like factor 1 (CKLF1) was recently identified as a novel cytokine. The full-length CKLF1 cDNA contains 530 bp encoding 99 amino acid residues with a CC motif similar to that of other CC family chemokines. Recombinant CKLF1 exhibits chemotactic activity on leucocytes and stimulates proliferation of murine skeletal muscle cells. We questioned whether CKLF1 could be involved in the pathogenesis of inflammation and proliferation in the lung. Therefore we used efficient in vivo gene delivery method to investigate the biological effect of CKLF1 in the murine lung.

Methods: CKLF1-expressing plasmid, pCDI-CKLF1, was constructed and injected into the skeletal muscles followed by electroporation. Lung tissues were obtained at the end of week 1, 2, 3 and 4 respectively after injection. The pathological changes in the lungs were observed by light microscope.

Results: A single intramuscular injection of CKLF1 plasmid DNA into BALB/c mice caused dramatic pathological changes in the lungs of treated mice. These changes included peribronchial leukocyte infiltration, epithelial shedding, collagen deposition, proliferation of bronchial smooth muscle cells and fibrosis of the lung.

Conclusions: The sustained morphological abnormalities of the bronchial and bronchiolar wall, the acute pneumonitis and interstitial pulmonary fibrosis induced by CKLF1 were similar to phenomena observed in chronic persistent asthma, acute respiratory distress syndrome and severe acute respiratory syndrome. These data suggest that CKLF1 may play an important role in the pathogenesis of these important diseases and the study also implies that gene electro-transfer in vivo could serve as a valuable approach for evaluating the function of a novel gene in animals.

Citing Articles

Role of chemokine-like factor 1 as an inflammatory marker in diseases.

Li Y, Yu H, Feng J Front Immunol. 2023; 14:1085154.

PMID: 36865551 PMC: 9971601. DOI: 10.3389/fimmu.2023.1085154.


Electronic-Cigarette Use Alters Nasal Mucosal Immune Response to Live-attenuated Influenza Virus. A Clinical Trial.

Rebuli M, Glista-Baker E, Hoffman J, Duffney P, Robinette C, Speen A Am J Respir Cell Mol Biol. 2020; 64(1):126-137.

PMID: 33095645 PMC: 7781000. DOI: 10.1165/rcmb.2020-0164OC.


Chemokine-like factor 1 (CKLF1) aggravates neointimal hyperplasia through activating the NF-κB /VCAM-1 pathway.

Liu X, Qu C, Zhang Y, Fang J, Teng L, Zhang R FEBS Open Bio. 2020; 10(9):1880-1890.

PMID: 32741140 PMC: 7459414. DOI: 10.1002/2211-5463.12942.


Chemokine-like factor 1: A promising therapeutic target in human diseases.

Cai X, Deng J, Ming Q, Cai H, Chen Z Exp Biol Med (Maywood). 2020; 245(16):1518-1528.

PMID: 32715782 PMC: 7553088. DOI: 10.1177/1535370220945225.


Chemokine-like factor 1-derived C-terminal peptides induce the proliferation of dermal microvascular endothelial cells in psoriasis.

Tan Y, Wang Y, Li L, Xia J, Peng S, He Y PLoS One. 2015; 10(4):e0125073.

PMID: 25915746 PMC: 4410955. DOI: 10.1371/journal.pone.0125073.